Uterine Cancer

Uterine Cancer Pedro T. Ramirez, M.D. Associate Professor Director of Minimally Invasive Research & Education Department of Gynecologic Oncology

Uterine Cancer ,[object Object],[object Object],[object Object],[object Object],[object Object]

Epidemiology ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Type I Endometrial Carcinoma ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Type II Endometrial Carcinoma ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

RISK FACTORS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Risk Factors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Familial Syndromes ,[object Object],[object Object],[object Object],[object Object]

Endometrial Cancer Screening ,[object Object],[object Object],[object Object],[object Object],[object Object]

Signs and Symptoms ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Diagnosis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Diagnosis: Gold Standard ,[object Object],[object Object],[object Object],[object Object],[object Object]

Endometrial Hyperplasia ,[object Object],[object Object]

Hyperplasia: Progression to Cancer ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Significant percentage (43%) of complex hyperplasia with atypia will have coexisting adenocarcinoma

Management: Hyperplasia NO ATYPIA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Management: Hyperplasia ATYPIA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Endometrial Carcinoma ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Important Histology Points ,[object Object],[object Object],[object Object],[object Object],[object Object]

Endometrial Cancer Grade ,[object Object],[object Object],[object Object],[object Object]

Synchronous Endometrial and Ovarian Cancer ,[object Object],[object Object],[object Object],[object Object],[object Object]

Pretreatment Evaluation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Endometrial Cancer Treatment ,[object Object],[object Object]

Primary Radiation Therapy ,[object Object],[object Object],[object Object],[object Object]

Hormone Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Surgical Treatment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Risk of Lymph Node Metastasis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Routine Lymphadenectomy ,[object Object],[object Object],[object Object]

Laparoscopic Staging ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Survival by Surgical Stage ,[object Object],[object Object],[object Object],[object Object],[object Object]

Prognostic Factors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Adjuvant Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Low Risk Endometrial Cancer ,[object Object],[object Object],[object Object]

Adjuvant Radiation Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Follow Up ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Recurrence ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Uterine Sarcoma ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Carcinosarcoma ,[object Object],[object Object],[object Object],[object Object]

Carcinosarcoma Survival ,[object Object],[object Object],[object Object],[object Object],[object Object]

Leiomyosarcoma ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Sarcoma Treatment: Surgery ,[object Object],[object Object],[object Object],[object Object]

Sarcoma Treatment: Radiation ,[object Object],[object Object]

Sarcoma Treatment: Recurrence ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Uterine Cancer

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Uterine Cancer

Similar to Uterine Cancer (20)

More from Gregorio Urruela Vizcaíno

More from Gregorio Urruela Vizcaíno (20)

Recently uploaded

Recently uploaded (20)

Uterine Cancer